AbbVie is hoping for regulatory approval this month of its first significant new drug product in a decade: a multidrug regimen for the liver disease hepatitis C. AbbVie currently relies on just one drug to generate 63% of its revenue: the anti-inflammatory drug Humira.
from WSJ.com: US Business http://ift.tt/1wj3sqX
via IFTTT
from WSJ.com: US Business http://ift.tt/1wj3sqX
via IFTTT
No comments:
Post a Comment